194 related articles for article (PubMed ID: 37121942)
21. Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models.
Gray TA; MacLaine NJ; Michie CO; Bouchalova P; Murray E; Howie J; Hrstka R; Maslon MM; Nenutil R; Vojtesek B; Langdon S; Hayward L; Gourley C; Hupp TR
J Immunol Methods; 2012 Apr; 378(1-2):20-32. PubMed ID: 22361111
[TBL] [Abstract][Full Text] [Related]
22. Atorvastatin Enhances Effects of Radiotherapy on Prostate Cancer Cells and Xenograft Tumor Mice Through Triggering Interaction Between Bcl-2 and MSH2.
He Z; Yuan J; Shen F; Zeng F; Qi P; Wang Z; Zhai Z
Med Sci Monit; 2020 Sep; 26():e923560. PubMed ID: 32870824
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
[TBL] [Abstract][Full Text] [Related]
24. Oleic acid promotes prostate cancer malignant phenotype via the G protein-coupled receptor FFA1/GPR40.
Liotti A; Cosimato V; Mirra P; Calì G; Conza D; Secondo A; Luongo G; Terracciano D; Formisano P; Beguinot F; Insabato L; Ulianich L
J Cell Physiol; 2018 Sep; 233(9):7367-7378. PubMed ID: 29663374
[TBL] [Abstract][Full Text] [Related]
25. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
Xue D; Lu H; Xu HY; Zhou CX; He XZ
J Cell Mol Med; 2018 Jun; 22(6):3223-3237. PubMed ID: 29633510
[TBL] [Abstract][Full Text] [Related]
26. EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis.
Du TQ; Liu R; Zhang Q; Luo H; Liu Z; Sun S; Wang X
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358967
[TBL] [Abstract][Full Text] [Related]
27. Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties.
Liu YQ; Wang SK; Xu QQ; Yuan HQ; Guo YX; Wang Q; Kong F; Lin ZM; Sun DQ; Wang RM; Lou HX
Acta Pharmacol Sin; 2019 May; 40(5):689-698. PubMed ID: 30171201
[TBL] [Abstract][Full Text] [Related]
28. The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling.
Waseem D; Khan GM; Haq IU; Rashid U; Syed DN
Toxicol Appl Pharmacol; 2020 Aug; 401():115091. PubMed ID: 32525019
[TBL] [Abstract][Full Text] [Related]
29. Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation.
Ciardiello C; Leone A; Lanuti P; Roca MS; Moccia T; Minciacchi VR; Minopoli M; Gigantino V; De Cecio R; Rippa M; Petti L; Capone F; Vitagliano C; Milone MR; Pucci B; Lombardi R; Iannelli F; Di Gennaro E; Bruzzese F; Marchisio M; Carriero MV; Di Vizio D; Budillon A
J Exp Clin Cancer Res; 2019 Jul; 38(1):317. PubMed ID: 31319863
[TBL] [Abstract][Full Text] [Related]
30. Silibinin inhibits fibronectin induced motility, invasiveness and survival in human prostate carcinoma PC3 cells via targeting integrin signaling.
Deep G; Kumar R; Jain AK; Agarwal C; Agarwal R
Mutat Res; 2014 Oct; 768():35-46. PubMed ID: 25285031
[TBL] [Abstract][Full Text] [Related]
31. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
33. An efficient method for native protein purification in the selected range from prostate cancer tissue digests.
Ahmad R; Nicora CD; Shukla AK; Smith RD; Qian WJ; Liu AY
Chin Clin Oncol; 2016 Dec; 5(6):78. PubMed ID: 28061542
[TBL] [Abstract][Full Text] [Related]
34. An overview of advances in multi-omics analysis in prostate cancer.
Zhang E; Zhang M; Shi C; Sun L; Shan L; Zhang H; Song Y
Life Sci; 2020 Nov; 260():118376. PubMed ID: 32898525
[TBL] [Abstract][Full Text] [Related]
35. Anaplastic Lymphoma Kinase Mutation (
Carneiro BA; Pamarthy S; Shah AN; Sagar V; Unno K; Han H; Yang XJ; Costa RB; Nagy RJ; Lanman RB; Kuzel TM; Ross JS; Gay L; Elvin JA; Ali SM; Cristofanilli M; Chae YK; Giles FJ; Abdulkadir SA
Clin Cancer Res; 2018 Jun; 24(12):2732-2739. PubMed ID: 29559559
[No Abstract] [Full Text] [Related]
36. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
Liang W; Wang F; Chen Q; Dai J; Escara-Wilke J; Keller ET; Zimmermann J; Hong N; Lu Y; Zhang J
J Cancer Res Clin Oncol; 2019 Aug; 145(8):1999-2012. PubMed ID: 31172267
[TBL] [Abstract][Full Text] [Related]
37. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
38. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer.
Li H; Gu J; Tian Y; Li S; Zhang H; Dai Z; Wang Z; Zhang N; Peng R
Front Immunol; 2022; 13():982628. PubMed ID: 36325340
[TBL] [Abstract][Full Text] [Related]
39. LQB-118 Suppresses Migration and Invasion of Prostate Cancer Cells by Modulating the Akt/GSK3β Pathway and MMP-9/Reck Gene Expression.
Martino T; DE Bem GF; Santos SVM; Coelho MGP; Resende AC; Netto C; Costa PRR; Justo G; Sabino KCC
Anticancer Res; 2023 Jan; 43(1):359-367. PubMed ID: 36585169
[TBL] [Abstract][Full Text] [Related]
40. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
